• An early-stage Vertex Pharmaceuticals focused on developing novel treatments for fibrosis and cancer.
• A clinical-stage Regeneron Pharmaceuticals focused on developing drugs for fibrosis and cancer.

Major products of Damora Therapeutics (DMRA):

• GB2064: A product candidate in Phase IIa for the treatment of myelofibrosis.
• GB0139: An inhaled galectin-3 inhibitor in Phase IIb for severe fibrotic lung diseases like idiopathic pulmonary fibrosis.
• GB1211: A selective oral galectin-3 inhibitor in Phase IIa for cancer and Phase Ib/IIa for fibrosis.

Damora Therapeutics (DMRA) is a clinical-stage biotechnology company focused on developing molecules for the treatment of fibrosis, cancer, inflammation, and other related diseases. Its product candidates, such as GB2064, GB0139, and GB1211, are currently in various phases of clinical trials (Phase IIa, Phase IIb, and Phase Ib/IIa).

As a clinical-stage biotechnology company with no commercialized products on the market, Damora Therapeutics does not currently have major customers, either individuals or other companies, who purchase its products or services.

• Lonza Ltd. (SIX: LONN)
• Callery Chemicals (Parent: MSA Safety Incorporated (NYSE: MSA))
• Hovione LLC
• Siegfried AG (SIX: SFZN)

Sherwin Sattarzadeh, Interim Principal Executive Officer & Chief Operating Officer

Sherwin Sattarzadeh was appointed Interim Principal Executive Officer in February 2026, after serving as Chief Operating Officer since January 2026. He brings over two decades of industry experience in drug development and company lifecycle. Prior to joining Galecto (now Damora Therapeutics), he served as Chief Business Officer at Blueprint Medicines Corporation from January 2025 to October 2025. During his 10 years at Blueprint Medicines, Mr. Sattarzadeh held various positions of increasing responsibility, including Head of Regulatory Affairs, Chief of Staff, and SVP Strategic Operations. He has a background in hematology/oncology and rare disease drug development, having contributed to the global approvals of therapies such as AYVAKIT® (avapritinib) and GAVRETO® (pralsetinib).

Lori Firmani, Chief Financial Officer

Lori Firmani was appointed Chief Financial Officer in November 2025, having previously served as Interim Chief Financial Officer and Vice President, Finance and Corporate Controller. She possesses over 25 years of experience in financial roles within the biotech sector. Ms. Firmani served as Chief Financial Officer of Spring Bank Pharmaceuticals, Inc. from April 2020 until its acquisition in November 2020.

Becker Hewes, M.D., Chief Medical Officer

Dr. Becker Hewes was appointed Chief Medical Officer in January 2026. He brings over two decades of experience in drug development in public biotechnology companies. Most recently, he served as Chief Medical Officer at Blueprint Medicines, where he led the development of an industry-leading pipeline and the approval of AYVAKIT® (avapritinib) for indolent and advanced systemic mastocytosis. His previous experience in hematology/oncology drug development includes leading clinical development and translational medicine efforts for multiple early-stage oncology programs and registration programs for therapies like Kisqali® (ribociclib) and Bosulif® (bosutinib).

Garrett Winslow, General Counsel and Corporate Secretary

Garrett Winslow serves as General Counsel and Corporate Secretary, and also holds the title of Senior Vice President. He has more than 15 years of experience working with public companies in the life sciences industry.

Matthew Kronmiller, Executive Vice President of Strategy and Chief Business Officer

Matthew Kronmiller holds the position of Executive Vice President of Strategy and Chief Business Officer.

Damora Therapeutics (NASDAQ: DMRA) focuses on developing therapeutics for mutant calreticulin (mutCALR)-driven myeloproliferative neoplasms (MPNs), which include essential thrombocythemia (ET) and myelofibrosis (MF).

The addressable market for Damora Therapeutics' main products, which target mutCALR-driven MPNs, is approximately 42,000 patients in the United States.

1. Advancement of the DMR-001 Program: The successful progression of DMR-001, an antibody therapeutic for mutant-calreticulin essential thrombocythemia and myelofibrosis, is a key driver. The company anticipates submitting an Investigational New Drug (IND) or Clinical Trial Application (CTA) for DMR-001 in mid-2026, with two clinical proof-of-concept datasets expected beginning mid-2027. Positive outcomes from these milestones would significantly de-risk the asset, making it more attractive for potential licensing deals or future commercialization.
2. Progression of Additional Oncology Pipeline Candidates (DMR-002, DMR-003, GB3226): Damora Therapeutics plans to submit an IND or CTA for DMR-002 in the second half of 2026 and for DMR-003 in 2027. Additionally, the preclinical drug GB3226 for acute myeloid leukemia (AML) has an IND submission planned for Q1 2026. Successfully moving these candidates into clinical trials expands the company's pipeline and creates additional opportunities for future value creation, including potential partnership revenue.
3. Positive Clinical Trial Results and Advancement of GB1211 and GB0139: The company's ongoing clinical programs for GB1211 (a galectin-3 inhibitor in Phase IIa for cancer and Phase Ib/IIa for fibrosis, and also indicated for liver disease) and GB0139 (an inhaled galectin-3 inhibitor in Phase IIb for severe fibrotic lung diseases like idiopathic pulmonary fibrosis) represent crucial near-term value inflection points. Favorable results from these trials would validate the company's therapeutic approach, enhance the attractiveness of these assets, and bring them closer to potential market approval or licensing agreements.
4. Strategic Partnerships and Licensing Agreements: As a clinical-stage biotechnology company without current product sales, revenue growth for Damora Therapeutics is highly dependent on securing strategic collaborations and licensing agreements for its promising drug candidates. Successful progression through clinical milestones, particularly positive proof-of-concept data, would make the company's assets more appealing to larger pharmaceutical partners, potentially generating upfront payments and milestone-based revenues.

Share Issuance

• In February 2026, Galecto, Inc., now Damora Therapeutics, completed a public offering of common stock, raising approximately $316.3 million in gross proceeds by issuing 16,644,737 shares.
• Galecto also filed a mixed shelf registration for up to $150 million in February 2026, providing flexibility for future security issuances.
• On August 29, 2024, Galecto implemented a 1-for-25 reverse stock split of its common stock, primarily to maintain its Nasdaq listing compliance.

Inbound Investments

• In November 2025, concurrent with the acquisition of Damora Therapeutics, Galecto secured an oversubscribed private investment of approximately $285 million through a private placement of Series C non-voting convertible preferred stock.

Outbound Investments

• Galecto, Inc. completed the acquisition of privately held Damora Therapeutics, Inc. in November 2025. As part of this acquisition, Galecto issued 265,309 shares of common stock and various Series B and Series C preferred stock to Damora holders.

Capital Expenditures

• Research and development expenses for the year ended December 31, 2025, were $26.9 million, a significant increase from $6.4 million in 2024, primarily driven by preclinical study and clinical trial-related expenses, and chemistry, manufacturing, and control (CMC) activities.
• An acquired in-process research and development cost of $174.3 million was recognized in fiscal year 2025, which was associated with the asset acquisition of Damora Therapeutics.
• The company plans to use proceeds from recent offerings to fund preclinical studies, clinical trials, and manufacturing for its antibody programs, as well as general research and development activities.